(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
FRANKFURT (Reuters) - The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose ...
The new injector device is intended to allow adults to self-administer Acthar Gel with fewer steps. The Food and Drug Administration (FDA) has approved a new single-dose prefilled SelfJect ™ Injector ...
Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient ...
· The newly approved device delivers a pre‑set 7.2 mg once weekly maintenance dose of semaglutide in a single injection. Previously, the 7.2 mg dose was administered by taking three 2.4 mg injections ...
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results